As patients with tumours that harbour a somatic BRCA mutation may also benefit from treatment with PARP inhibitors, it is important to be able to test for BRCA1 and BRCA2 variants in tumour samples available after routine histopathology assessment and diagnosis. The gene discussed is BRCA1; the disease is neoplasm.